RxDoctor Payments Data

Katie Hampton, NP

Nurse Practitioner · Green Bay, WINPI 1073560314

Payments from drug & device makers

$2,297in general payments, 2019–2025

Across 48 payments — averaging $47.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$728
  • Novartis$321
  • Lexicon Pharmaceuticals, Inc.$230
  • Amgen$203
  • Kiniksa Pharmaceuticals International, PLC$135
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$125
  • plus $555 from 5 others

What the payments were for

  • Food & beverage$2,297100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,297 in reported general payments places this provider in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$31,624
Medicare patients
209
Services billed
527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban252$265,963
XareltoRivaroxaban76$95,751
EntrestoSacubitril/Valsartan39$40,084
Praluent PenAlirocumab11$10,153
Bumetanide81$4,412
Carvedilol285$4,077
Metoprolol Succinate293$3,904
Potassium Chloride170$3,421
Furosemide369$2,798
Diltiazem 24hr Er (Cd)Diltiazem Hcl78$2,239
Digoxin111$2,229
Rosuvastatin Calcium150$2,073
Atorvastatin Calcium199$2,026
Metoprolol Tartrate225$1,837
Amiodarone Hcl65$1,795

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$116$95,75176 claims
NovartisEntresto$321$40,08439 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →